FIELD: pharmaceuticals.
SUBSTANCE: invention relates to the use of the tripeptide Leu-Ile-Lys (leucine – isoleucine – lysine) as a pharmacological agent for the treatment of urinary stone disease.
EFFECT: advantages of the claimed invention are high anti-lithogenic activity.
1 cl, 2 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF PROTEOMIC CORRECTION OF OXALATE NEPHROLITHIASIS | 2019 |
|
RU2704022C1 |
| PHARMACOLOGICAL AGENT FOR THE TREATMENT OF URATE NEPHROPATHY | 2021 |
|
RU2760949C1 |
| REMEDY FOR THE TREATMENT OF URATE NEPHROLITHIASIS | 2021 |
|
RU2762139C1 |
| AGENT ANTILITAL POSSESSING ANTILITOGENIC ACTION | 2012 |
|
RU2484834C1 |
| PROCESS FOR PREPARATION OF A PEPTIDE AGENT WITH ANTILITHOGENIC EFFECT | 2017 |
|
RU2652339C1 |
| METHOD FOR PREDICTING URATE NEPHROLITHIASIS | 2021 |
|
RU2759237C1 |
| PHARMACOLOGICAL AGENT FOR THE TREATMENT OF GASTRIC ULCER | 2018 |
|
RU2688187C1 |
| PHYTOAGENT "NEFROLIT" FOR TREATMENT AND PROPHYLAXIS OF UROLITHIASIS DISEASE | 2002 |
|
RU2218170C1 |
| METHOD FOR REHABILITATION OF PATIENTS WITH RENAL DISEASE | 1999 |
|
RU2177324C2 |
| AGENT FOR PREVENTING AND TREATING UROLITHIASIS | 2015 |
|
RU2580282C1 |
